AC
KYTH

Ascend Capital’s KYTHERA BIOPHARMACEUTICALS, INC COM KYTH Stock Holding History

Ascend Capital’s Portfolio KYTH Stock Details KYTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-91,435
Closed -$3.17M – 234
2014
Q4 		$3.17M Buy
91,435
+2,965
+3% +$103K 0.12% 136
2014
Q3 		$2.9M Buy
88,470
+1,262
+1% +$44.4K 0.09% 157
2014
Q2 		$3.35M Buy
87,208
+1,216
+1% +$42.4K 0.11% 147
2014
Q1 		$3.42M Buy
85,992
+5,307
+7% +$237K 0.09% 157
2013
Q4 		$3.01M Sell
80,685
-2,109
-3% -$87.5K 0.09% 155
2013
Q3 		$3.77M Sell
82,794
-25,707
-24% -$769K 0.14% 154
2013
Q2 		$2.94M Buy
+108,501
New +$2.48M 0.12% 136

Other funds holding KYTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Ascend Capital's KYTH Position: Q1 2015 in Review

Ascend Capital sold out of KYTHERA BIOPHARMACEUTICALS, INC COM (KYTH) in Q1 2015, closing a stake of 91,435 shares — an estimated $3.17M sold.

Ascend Capital first reported a position in KYTH in Q2 2013 and held it in 7 quarters. The position peaked at $3.77M in Q3 2013. 126 funds tracked by Wall St. Rank hold KYTH as of Q1 2015.

  • Ascend Capital reported no remaining KYTHERA BIOPHARMACEUTICALS, INC COM position as of Q1 2015 after selling out during the quarter.
  • Ascend Capital sold 91,435 KYTHERA BIOPHARMACEUTICALS, INC COM shares in Q1 2015, an estimated $3.17M.
  • Ascend Capital first reported a position in KYTHERA BIOPHARMACEUTICALS, INC COM in Q2 2013 and held it in 7 quarters.
  • Ascend Capital's KYTHERA BIOPHARMACEUTICALS, INC COM position peaked at $3.77M in Q3 2013.
  • 126 funds tracked by Wall St. Rank held KYTHERA BIOPHARMACEUTICALS, INC COM as of Q1 2015.

Based on Ascend Capital's 13F filing for Q1 2015, filed 14 May 2015.